This Week on Drug Topics: May 31 to June 4

Article

Here’s a preview of the featured content to watch for this week on Drug Topics®.

the latest news updates

Coronavirus Research News

The CDC estimates that more than 62% of US adults have received at least 1 dose of a COVID-19 vaccine as of this article’s press time. Keeping up with pandemic news is more important than ever, so check back to Drug Topics® to stay informed on the latest coronavirus-related news and research.

Read more coronavirus-related news.

The Latest from Total Pharmacy®: NCPA Urges for Transparency, Consistency in Medicare Part D Reporting Requirements

The National Community Pharmacists Association (NCPA) is urging the Centers for Medicare & Medicaid Services (CMS) to require full transparency and consistency in Medicare Part D Reporting Requirements for community pharmacies.

Read more

Drug Topics® Journal, June 2021 Digital Edition

The June 2021 digital edition of Drug Topics Journal will soon be available on DrugTopics.com. In this issue,you’ll find great insights into the latest pharmacy trends in independent community practice, technology, autoimmune diseases, and more.

Read and download recent journal issues.

New Over the Counter Podcast Episode

In our newest podcast episode, Megan Numrich, director, support services, Macro Helix, will be talking about HRSA audits and how what pharmacists need to know to effectively prepare for an audit.

Listen to past Over the Counter episodes.

On Demand: Helping Retail and Specialty Pharmacies Use the Right Analytics to Unlock Value Beyond Prescription Reimbursements

Pharmacies are a trusted healthcare destination in their communities. But shrinking reimbursements continue to hinder growth and stretch resources. This on demand webinar explains how pharmacies can use the power of data to drive sustainable growth.

Watch the webinar on demand.

In Case You Missed It: FDA Issues EUA to GSK for COVID-19 Treatment Sotrovimab

Sotrovimab is authorized to treat COVID-19 patients 12 years of age and older with mild-to-moderate infection and who are at high risk for severe disease progression.

Read more

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.